English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 852206      Online Users : 1430
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version
    Siblings
    圖書 [1/1]
    期刊論文 [327/330]

    Collection Statistics

    近3年內發表的文件:16(8.94%)
    含全文筆數:115(64.25%)

    文件下載次數統計
    下載大於0次:115(100.00%)
    下載大於100次:112(97.39%)
    檔案下載總次數:39002(22.05%)

    最後更新時間: 2024-11-28 14:55


    Top Upload

    Loading...

    Top Download

    Loading...

    RSS Feed RSS Feed
    Jump to a point in the index:
    Or type in a year:
    Ordering With Most Recent First Show Oldest First

    Showing items 76-100 of 179. (8 Page(s) Totally)
    << < 1 2 3 4 5 6 7 8 > >>
    View [10|25|50] records per page

    DateTitleRelation
    2017-09 A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02) Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 617O.
    2017-06-26 Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD - 018.
    2017-06-26 CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD-017.
    2017-05 The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM Journal of Clinical Oncology. 2017 May;35:Meeting Abstract e15795.
    2017-02 Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):303.
    2017-02 A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):417.
    2017-02 Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):2.
    2017-02 Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV Journal of Clinical Oncology. 2017 Feb;35(4):Meeting Abstract 293.
    2016-12 Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 221PD.
    2016-12 Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1 Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 242P.
    2016-12 Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 420P.
    2016-11 Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer Journal of Gastroenterology and Hepatology. 2016 Nov;31(Suppl. 3):245.
    2016-10 Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-b Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):259.
    2016-10 Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with ge Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):260.
    2016-10 Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 622PD.
    2016-10 Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 693P.
    2016-10 CagA and NFAT co-operatively participate in the lymphomagenesis of gastric MALT lymphoma Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 933P.
    2016-09 Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: Results from t Annals of Oncology. 2016 Sep;27(Suppl. 4):Meeting Abstract B04.
    2016-06 Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study Annals of Oncology. 2016 Jun;27(Suppl. 2):ii84.
    2016-06 Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine Annals of Oncology. 2016 Jun;27(Suppl. 2):119.
    2016-06 Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Annals of Oncology. 2016 Jun;27(Suppl. 2):110.
    2016-05 Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine Journal of Clinical Oncology. 2016 May;34(15, Suppl.):Meeting Abstract 4126.
    2016-05 Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15740.
    2016-05 Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number 4017.
    2016-05 Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15732.

    Showing items 76-100 of 179. (8 Page(s) Totally)
    << < 1 2 3 4 5 6 7 8 > >>
    View [10|25|50] records per page

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback